このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Preliminary Efficacy of a Remote Cardiac Rehabilitation Program in Pediatric Patients With Complex Congenital Heart Disease

2026年5月6日 更新者:Sung Eun Hyun、Seoul National University Hospital

Preliminary Efficacy of a Community-Based Remote Cardiac Rehabilitation Program on Cardiopulmonary Function and Quality of Life in Pediatric Patients With Complex Congenital Heart Disease: A Single Blind, Randomized Controlled Trial

This study aims to evaluate the preliminary efficacy of a 12-week community-based remote cardiac rehabilitation program on cardiopulmonary function and quality of life in pediatric patients (aged 8 to 18 years) with complex congenital heart disease. Participants will be randomly assigned to either an experimental group receiving the remote cardiac rehabilitation program or a control group receiving the standard of care.

調査の概要

研究の種類

介入

入学 (推定)

45

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Sungbae Jo Research Professor, Ph.D
  • 電話番号:82-2-2072-4178
  • メール:sungbaejo@snuh.org

研究場所

      • Seoul、韓国、03080
        • 募集
        • Seoul National University Hospital
        • コンタクト:
          • Sungbae Jo Research Professor, Ph.D
          • 電話番号:82-2-2072-4178
          • メール:sungbaejo@snuh.org

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Aged 8 to 18 years.
  • Diagnosed with complex congenital heart disease (e.g., single ventricle, transposition of the great arteries) and have a history of cardiac surgery.
  • At least 3 months post-cardiac surgery and maintaining a stable hemodynamic status.
  • Capable of utilizing remote programs (mobile apps, video platforms, etc.) in the home environment with technical support from guardians.
  • Participant or guardian has agreed to participate and signed the written informed consent form.
  • Confirmed to have decreased physical activity level and physical well-being through assessments (Must meet both):
  • KIDSCREEN-27 Parent Proxy-report 'Physical well-being' domain T-score of 40 or below.
  • Exercise Vital Sign (EVS) survey indicating moderate-to-vigorous physical activity (MVPA) time of less than 420 minutes per week.

Exclusion Criteria:

  • Ongoing cardiovascular diseases such as uncontrolled arrhythmia, acute heart failure, myocarditis, or pericarditis.
  • Neurological or musculoskeletal disorders that make independent exercise impossible.
  • Cognitive impairment that prevents understanding or following the instructions of the remote rehabilitation program.
  • Clinical levels of depression or anxiety restricting exercise participation, as determined by the attending physician (assessed via Korean Children's Depression Inventory 2: Self-Report [K-CDI-2:SR] and Revised Children's Manifest Anxiety Scale, Second Edition [RCMAS-2]).
  • Inability to cooperate with study tests, such as the Cardiopulmonary Exercise Test (CPET), Electrocardiogram (ECG), and 6-Minute Walk Test (6MWT).
  • Currently wearing an artificial pacemaker.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Remote Cardiac Rehabilitation Group
Participants randomly assigned to this group will receive a 12-week remote cardiac rehabilitation program followed by a 12-week follow-up period (total 24 weeks).
The program consists of supervised remote exercise via ZOOM once a week (approx. 60 minutes, including warm-up, aerobic, resistance, respiratory, and cool-down exercises) and self-directed exercise 3 to 7 times a week. Biological signals (ECG, heart rate, SpO2) are monitored using wearable devices (mobiCARE, pulse oximeter, and smartwatch). A respiratory muscle training device (POWERbreathe) is also utilized.
Participants will maintain their usual outpatient care, medications, and standard physical activity guidelines for without the remote structured intervention.
アクティブコンパレータ:Control Group
Participants randomly assigned to this group will receive the standard of care for 24 weeks. After the 24-week evaluation, they will be offered a 1-month exercise education program opportunity.
Participants will maintain their usual outpatient care, medications, and standard physical activity guidelines for without the remote structured intervention.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Maximal Oxygen Consumption (VO2 max)
時間枠:Baseline (Week 0), 12 weeks
Measured by Cardiopulmonary Exercise Test (CPET) using the OSAKA protocol. It assesses the maximal amount of oxygen the body can utilize during exercise.
Baseline (Week 0), 12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Pediatric Quality of Life Inventory (PedsQL) Total Score
時間枠:Baseline (Week 0), 12 weeks, 24 weeks
Health-related quality of life assessed by the PedsQL questionnaire. Total scores range from 0 to 100, where higher scores indicate a better outcome (higher health-related quality of life).
Baseline (Week 0), 12 weeks, 24 weeks
Cardiac Rehabilitation Program Attendance Rate
時間枠:12 weeks, 24 weeks
Calculated as the number of participated sessions divided by the total number of provided sessions (%).
12 weeks, 24 weeks
Drop-out Rate
時間枠:12 weeks, 24 weeks
Percentage of participants who dropped out related to the intervention
12 weeks, 24 weeks
Change in Physical Activity Level
時間枠:Baseline, 12 weeks, 24 weeks
Measured by an accelerometer (GENEActiv) worn for 7 days and smartwatch data.
Baseline, 12 weeks, 24 weeks
Change in Global Physical Activity Questionnaire (GPAQ) Score
時間枠:Baseline, 12 weeks, 24 weeks
Assesses levels of physical activity in three domains (activity at work/school, travel to and from places, recreational activities) and sedentary behavior. The Global Physical Activity Questionnaire (GPAQ) calculates physical activity volume in Metabolic Equivalent of Task (MET)-minutes per week, with a minimum value of 0 and no defined maximum limit, where higher values indicate a better outcome (greater physical activity).
Baseline, 12 weeks, 24 weeks
Change in Pediatric Quality of Life Inventory (PedsQL) Parent Proxy-Report Score
時間枠:Baseline, 12 weeks, 24 weeks
Assesses health-related quality of life of the pediatric patient from the perspective of the parents or guardians. Total scores range from 0 to 100, where higher scores indicate a better outcome (higher health-related quality of life).
Baseline, 12 weeks, 24 weeks
Change in Pediatric Quality of Life Inventory (PedsQL) Cardiac Module Score
時間枠:Baseline, 12 weeks, 24 weeks
A disease-specific module designed to measure health-related quality of life specifically in pediatric patients with heart disease. Total scores range from 0 to 100, where higher scores indicate a better outcome (better disease-specific quality of life).
Baseline, 12 weeks, 24 weeks
Change in Pediatric Quality of Life Inventory (PedsQL) Cardiac Module Parent Proxy-Report Score
時間枠:Baseline, 12 weeks, 24 weeks
A disease-specific module designed to measure health-related quality of life specifically in parent proxy-report of pediatric patients with heart disease. Total scores range from 0 to 100, where higher scores indicate a better outcome (better disease-specific quality of life).
Baseline, 12 weeks, 24 weeks
Change in Resilience Scale for Youth (RS-Y) Score
時間枠:Baseline, 12 weeks, 24 weeks
Assesses the level of psychological resilience in children and adolescents. Total scores range from 37 to 185 (based on 37 items), where higher scores indicate a better outcome (greater psychological resilience).
Baseline, 12 weeks, 24 weeks
Change in Child Behavior Checklist (CBCL) Score
時間枠:Baseline, 12 weeks, 24 weeks
Evaluates behavioral and emotional problems in children and adolescents, as reported by parents or guardians. Results are reported as T-scores typically ranging from 28 to 100, where higher scores indicate a worse outcome (more severe behavioral or emotional problems).
Baseline, 12 weeks, 24 weeks
Change in Korean Children's Depression Inventory 2: Self-Report (K-CDI-2:SR) Score
時間枠:Baseline, 12 weeks, 24 weeks
A self-report assessment to evaluate the presence and severity of depressive symptoms in children and adolescents. Scores range from 0 to 56, where higher scores indicate a worse outcome (more severe depressive symptoms).
Baseline, 12 weeks, 24 weeks
Change in Revised Children's Manifest Anxiety Scale, Second Edition (RCMAS-2) Score
時間枠:Baseline, 12 weeks, 24 weeks
A self-report instrument designed to assess the level and nature of anxiety in children and adolescents. Results are reported as scores typically ranging from 0 to 40, where higher scores indicate a worse outcome (greater severity of anxiety).
Baseline, 12 weeks, 24 weeks
Incidence of Adverse Events (Safety)
時間枠:12 weeks, 24 weeks
Proportion and rate of adverse events and serious adverse events occurring during exercise.
12 weeks, 24 weeks
Change in Oxygen Consumption (VO2)
時間枠:Baseline, 12 weeks, 24 weeks
The volume of oxygen consumed per minute during the cardiopulmonary exercise test. Unit: L/min.
Baseline, 12 weeks, 24 weeks
Change in Carbon Dioxide Production (VCO2)
時間枠:Baseline, 12 weeks, 24 weeks
The volume of carbon dioxide produced per minute during the cardiopulmonary exercise test. Unit: L/min.
Baseline, 12 weeks, 24 weeks
Change in Respiratory Exchange Ratio (RER)
時間枠:Baseline, 12 weeks, 24 weeks
The ratio of carbon dioxide production to oxygen consumption during the cardiopulmonary exercise test. Unit: Ratio
Baseline, 12 weeks, 24 weeks
Change in Minute Ventilation (VE)
時間枠:Baseline, 12 weeks, 24 weeks
The total volume of air inhaled and exhaled per minute during the cardiopulmonary exercise test. Unit: L/min.
Baseline, 12 weeks, 24 weeks
Change in Ventilatory Equivalent for Oxygen (VE/VO2)
時間枠:Baseline, 12 weeks, 24 weeks
The ratio of minute ventilation to oxygen consumption, reflecting ventilatory efficiency. Unit: Ratio
Baseline, 12 weeks, 24 weeks
Change in Ventilatory Equivalent for Carbon Dioxide (VE/VCO2)
時間枠:Baseline, 12 weeks, 24 weeks
The ratio of minute ventilation to carbon dioxide production, reflecting ventilatory efficiency. Unit: Ratio
Baseline, 12 weeks, 24 weeks
Change in Oxygen Pulse (O2 Pulse)
時間枠:Baseline, 12 weeks, 24 weeks
The amount of oxygen consumed per heart beat during the cardiopulmonary exercise test. Unit: mL/beat.
Baseline, 12 weeks, 24 weeks
Change in Peripheral Capillary Oxygen Saturation (SpO2)
時間枠:Baseline, 12 weeks, 24 weeks
The blood oxygen saturation level measured via pulse oximetry during the cardiopulmonary exercise test. Unit: %.
Baseline, 12 weeks, 24 weeks
Change in Maximal Heart Rate (HRmax)
時間枠:Baseline, 12 weeks, 24 weeks
The highest heart rate achieved during the cardiopulmonary exercise test. Unit: beats per minute (bpm).
Baseline, 12 weeks, 24 weeks
Change in Skeletal Muscle Mass measured by Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline, 12 weeks, 24 weeks
The total weight of skeletal muscle in the body measured by bioelectrical impedance analysis. Unit: kg.
Baseline, 12 weeks, 24 weeks
Change in Fat Mass measured by Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline, 12 weeks, 24 weeks
The total weight of fat in the body measured by bioelectrical impedance analysis. Unit: kg.
Baseline, 12 weeks, 24 weeks
Change in Percent Body Fat measured by Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline, 12 weeks, 24 weeks 13.
The percentage of total body weight that consists of fat, measured by bioelectrical impedance analysis. Unit: %.
Baseline, 12 weeks, 24 weeks 13.
Change in Abdominal Fat Ratio measured by Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline, 12 weeks, 24 weeks
The ratio of abdominal fat, evaluated by waist-to-hip circumference ratio via bioelectrical impedance analysis. Unit: %.
Baseline, 12 weeks, 24 weeks
Change in Extracellular Water Ratio measured by Bioelectrical Impedance Analysis (BIA)
時間枠:Baseline, 12 weeks, 24 weeks
The ratio of extracellular water to total body water, measured by bioelectrical impedance analysis. Unit: %.
Baseline, 12 weeks, 24 weeks
Change in Radial Artery Augmentation Index (AIx)
時間枠:Baseline, 12 weeks, 24 weeks
A measure of arterial stiffness derived from the radial artery pulse wave, standardized to a heart rate of 75 bpm (AIx@75). Unit: %.
Baseline, 12 weeks, 24 weeks
Change in Carotid-femoral Pulse Wave Velocity (c-f PWV)
時間枠:Baseline, 12 weeks, 24 weeks
The speed of the arterial pulse propagating from the carotid to the femoral artery, reflecting arterial stiffness. Unit: m/s.
Baseline, 12 weeks, 24 weeks
Change in Flow-Mediated Dilation (FMD)
時間枠:Baseline, 12 weeks, 24 weeks
The percentage increase in brachial artery diameter following a period of ischemia, assessing endothelial function. Unit: %.
Baseline, 12 weeks, 24 weeks
Change in 6-Minute Walk Test (6MWT) Distance
時間枠:Baseline, 12 weeks, 24 weeks
The total distance a participant can walk on a flat, hard surface in exactly 6 minutes. Unit: meters (m).
Baseline, 12 weeks, 24 weeks
Change in Lower Limb Strength measured by isokinetic dynamometer (Biodex)
時間枠:Baseline, 12 weeks, 24 weeks
The maximum isometric knee extension peak torque measured by an isokinetic dynamometer. Unit: Newton meters (N.m).
Baseline, 12 weeks, 24 weeks
Change in Lower Limb Muscular Endurance measured by 1-minute squats
時間枠:Baseline, 12 weeks, 24 weeks
The total number of chair stand squats completed within exactly one minute. Unit: repetitions.
Baseline, 12 weeks, 24 weeks
Change in Upper Limb Strength (Grip Strength)
時間枠:Baseline, 12 weeks, 24 weeks
The maximum isometric handgrip strength measured using a hand dynamometer. Unit: kg.
Baseline, 12 weeks, 24 weeks
Change in Flexibility measured by sit and reach test
時間枠:Baseline, 12 weeks, 24 weeks
The maximum distance reached forward while sitting with legs extended, assessing lower back and hamstring flexibility. Unit: cm.
Baseline, 12 weeks, 24 weeks
Change in Maximal Inspiratory Pressure (MIP)
時間枠:Baseline, 12 weeks, 24 weeks
The maximum pressure generated during inspiration against an occluded airway, assessing respiratory muscle strength. Unit: mmH2O.
Baseline, 12 weeks, 24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年5月1日

一次修了 (推定)

2029年10月31日

研究の完了 (推定)

2029年12月31日

試験登録日

最初に提出

2026年4月23日

QC基準を満たした最初の提出物

2026年5月6日

最初の投稿 (実際)

2026年5月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月7日

QC基準を満たした最後の更新が送信されました

2026年5月6日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する